Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
LetterLetters: Observations

Elevated C-Reactive Protein Levels Do Not Correspond to Autoimmunity in Type 1 Diabetes

Andras Treszl, Laszlo Szereday, Alessandro Doria, George L. King, Tihamer Orban
DOI: 10.2337/diacare.27.11.2769 Published 1 November 2004
Andras Treszl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Laszlo Szereday
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Alessandro Doria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
George L. King
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site
Tihamer Orban
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Find this author on ADS search
  • Find this author on Agricola
  • Search for this author on this site

A large body of data now supports that high normal or elevated C-reactive protein (CRP) levels are a marker of ongoing low-grade chronic inflammatory process and may predict a higher risk for cardiovascular disease. Type 1 diabetes is a T-cell-mediated disease (1), and autoantibodies (2) are considered to be the surrogate markers for the autoimmune process and have been used for disease prediction (3). However, little is known about the relationship between diabetes autoimmunity and the acute-phase response. We studied the relationship of islet cell autoimmunity in type 1 diabetes as reflected by the presence of GAD65 and ICA512 autoantibodies and CRP titers. We analyzed the following five groups of individuals: pre-diabetic (n = 10), new-onset (n = 29), long-term type 1 diabetic (n = 16), and long-term type 2 diabetic (n = 55) patients and healthy subjects (n = 50). CRP levels were significantly higher in long-term type 1 diabetic patients (0.11 mg/dl [range 0.014–1.39]) than in either new-onset type 1 diabetic patients (0.061 mg/dl [0.012–1.12], P = 0.04) or healthy control subjects (0.06 mg/dl [0.007–1.33], P = 0.02). Long-term type 2 diabetic patients have higher CRP levels (0.24 mg/dl [0.03–4.41]) than healthy control subjects (P = 0.04). We could not find any correlation between CRP levels and any combination or titer of autoantibodies in pre-diabetic, new-onset, and long-term type 1 diabetic patients.

The lack of elevated CRP in the pre-diabetic and recently diagnosed patients with type 1 diabetes is consistent with the notion that chronic localized autoimmune inflammation does not result in appreciable changes in the CRP levels, thus making it unsuitable as a marker of type 1 diabetic autoimmunity. The difference in CRP levels in long-term and new-onset type 1 diabetic patients may be related in part to the vanish of the intrinsic physiologically secreted insulin once extending the honeymoon period in type 1 diabetes. Insulin has been shown to have anti-inflammatory properties, including downregulation of acute-phase protein production of the liver (4); thus, it may lead to lower CRP levels.

The underlying mechanisms behind elevated CRP levels in long-term type 1 and type 2 diabetic patients might be different, as elevated glucose levels as well as insulin resistance are contributing factors to the inflammatory process. Prolonged elevated blood glucose levels are implicated in chronic inflammatory changes in the tissues in both type 1 and type 2 diabetic patients and reflected by the elevated CRP values. However, in type 2 diabetes, insulin resistance is also likely to be a major factor (5), as elevated CRP values have been found in near-normoglycemic pre-diabetic type 2 diabetic and metabolic syndrome patients.

Footnotes

  • DIABETES CARE

References

  1. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, Roep BO: Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 345:1036–1040, 2001
  2. Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221–229, 2001
  3. Liu E, Eisenbarth GS: Type 1A diabetes mellitus-associated autoimmunity. Endocrinol Metab Clin North Am 31:391–410, 2002 [review vii–viii]
  4. Dandona P, Aljada A, Mohanty P: The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45:924–930, 2002
  5. Haffner SM: Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 92:18J–26J, 2003

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.